Analysing Impurities and Degradation Products
DOI:
https://doi.org/10.61427/jcpr.v3.i3.2023.113Keywords:
Degradation Products, Impurities, Pharmaceutical AnalysisAbstract
In the realm of pharmaceutical analysis, the analysis of impurities and degradation products takes centre stage, and its significance cannot be overstated. These undesired substances can profoundly impact the quality, safety and efficacy of pharmaceutical products, necessitating rigorous analytical methods and processes at every stage of drug development and manufacturing. Forced degradation studies are instrumental in identifying and characterizing impurities that may arise within a product, a pivotal source of information for quality control and regulatory compliance. Stability testing is integral to the batch release process, ensuring each product batch meets established stability criteria before entering the market. Stability testing and degradation studies are indispensable constituents of pharmaceutical analysis. They substantially contribute to preserving the quality, safety, and efficacy of pharmaceutical products. Beyond their regulatory mandates, these studies serve as proactive instruments for comprehending and supervising product stability across their life cycles. The insights gleaned from these endeavours inform critical judgments during drug development and manufacturing, ultimately assuring the welfare of patients and compliance with stringent regulatory requisites.
Downloads
References
Rubén M. Maggio, Natalia L. Calvo, Silvana E. Vignaduzzo, Teodoro S. Kaufman. Pharmaceutical impurities and degradation products: Uses and applications of NMR techniques. Journal of Pharmaceutical and Biomedical Analysis. 2014; 101: 102-22.
Prajapati Prajesh and Agrawal YK. Analysis and impurity identification in pharmaceuticals. Reviews in Analytical Chemistry. 2014; 33(2): 123-33.
USP Chapters <1086> Impurities in drug substances and drug products. USP 41. The United States Pharmacopeial Convention. August 1, 2018.
ICH Harmonised Tripartite Guideline. Impurities in new drug substances. Q3A(R2). ICH. 25 October 2006.
Kelce WR, Castle KE, Ndikum-Moffor FM, Patton LM. Drug substance and drug product impurities, now what? MOJ Toxicology. 2017; 3(1):9-13.
Baertschi SW. Analytical methodologies for discovering and profiling degradation related impurities. Trends in Analytical Chemistry. 2006; 25(8): 758-67.
Published
How to Cite
Issue
Section

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Most read articles by the same author(s)
- Slesha Kumar Kosuru, Ch. Hemalatha, K. Venkat, K. Jahnavi Sravanthi, V. Kondala Rao, M.V.K Tejaswini, Santhosh Kumar Gandham, Formulation and Characterization of Copper Oxide Solid Lipid Micro-Particles , Journal of Clinical and Pharmaceutical Research: JCPR Volume:5/Issue:3 (2025)

.